GC Therapeutics (GCTx) has launched with $75 million in total capital.  GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome (Transcription-Factor-ome), was invented and developed by scientists in the lab of Professor George Church at Harvard Medical School and the Wyss Institute.  It integrates synthetic biology, gene editing, cell engineering and machine learning, with the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!